Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Moodys
Medtronic
UBS
Farmers Insurance
US Army
AstraZeneca
Argus Health

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLINZA

« Back to Dashboard

Clinical Trials for Zolinza

Trial ID Title Status Sponsor Phase Summary
NCT00121225 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00127101 An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) Terminated Merck Sharp & Dohme Corp. Phase 1 This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.
NCT00132002 Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer Terminated National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zolinza

Condition Name

Condition Name for Zolinza
Intervention Trials
Lymphoma 10
Unspecified Adult Solid Tumor, Protocol Specific 10
Recurrent Adult Acute Myeloid Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zolinza
Intervention Trials
Lymphoma 32
Leukemia 22
Leukemia, Myeloid, Acute 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zolinza

Trials by Country

Trials by Country for Zolinza
Location Trials
United States 500
Canada 32
Australia 5
Japan 5
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zolinza
Location Trials
Texas 38
California 30
Pennsylvania 29
Maryland 24
New York 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zolinza

Clinical Trial Phase

Clinical Trial Phase for Zolinza
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 2
Phase 2 45
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zolinza
Clinical Trial Phase Trials
Completed 59
Active, not recruiting 33
Recruiting 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zolinza

Sponsor Name

Sponsor Name for Zolinza
Sponsor Trials
National Cancer Institute (NCI) 75
Merck Sharp & Dohme Corp. 30
M.D. Anderson Cancer Center 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zolinza
Sponsor Trials
Other 116
NIH 77
Industry 47
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
UBS
Mallinckrodt
Baxter
Healthtrust
Citi
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.